You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • 2 year inhaled corticosteroid therapy did not prevent asthma in high risk preschool children after treatment was discontinued

Article Text

Article menu
Download PDFPDF
Therapeutics
2 year inhaled corticosteroid therapy did not prevent asthma in high risk preschool children after treatment was discontinued

https://doi.org/10.1136/ebm.11.6.174

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985–97.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In preschool children at high risk of asthma, does 2 year inhaled corticosteroid (IC) therapy prevent asthma after treatment is discontinued?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Allergy & immunology ★★★★★★☆ Respirology ★★★★★★☆ Paediatrics ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    {concealed*}†.

    Embedded ImageBlinding:

    blinded (patients, healthcare providers, {data collectors, and outcome assessors}†).*

    Embedded ImageFollow up period:

    up to 3 years.

    Embedded ImageSetting:

    5 clinical centres in the US.

    Embedded ImagePatients:

    285 children 2–3 years of age (mean age 3 y, 62% boys) who had wheezing or allergy without other clinically significant medical disorders, were at high risk of the persistence of asthma-like symptoms during their school year, had received ICs for ⩽4 months, and did not require ICs during a run in month.

    Embedded ImageIntervention:

    an IC (fluticasone propionate, GlaxoSmithKline), 88 µg twice daily (n = 143), …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • For correspondence: Dr T W Guilbert, University of Arizona, Tucson, AZ, USA. guilbert{at}arc.arizona.edu

    • Sources of funding: National Heart, Lung, and Blood Institute; National Institutes of Health; National Jewish Medical and Research Centre.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 191-191 Published Online First: 30 Nov 2006. doi: 10.1136/ebm.11.6.191-a